INmune Bio stock has October 29 earnings after USD 1.3 million loss

Published on 10/17/2026 at 19:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter loss was USD 1.3 million after impairment. INmune Bio stock stood at USD 1.57 on October 16, 2026, down 4.85 percent versus USD 1.65.

Earnings date and valuation

INmune Bio's next quarterly report is estimated for October 29, 2026.
The second-quarter net loss was USD 1.3 million versus USD 24.5 million in the prior year.
INmune Bio stock stood at USD 1.57 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.85 percent versus the prior close of USD 1.65.
INMB had a USD 43.6 million market capitalization and a negative P/E ratio of 2.28 as of October 16, 2026.

INMB, US45782T1051, Illustration mit AI erstellt.

INmune Bio's next quarterly report is estimated for October 29, 2026, according to MarketBeat in an October 6, 2026 earnings preview. In the second quarter of 2026, the company posted a USD 1.3 million net loss versus USD 24.5 million a year earlier, while INmune Bio stock last stood at USD 1.57 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.85 percent versus the prior close of USD 1.65.

Second-quarter loss narrows

SquawkNews summarized the company's second-quarter call on October 12, 2026. The loss improvement included a USD 16.5 million impairment charge in the prior-year period. Research and development produced a USD 0.8 million benefit in the second quarter of 2026, compared with USD 5.8 million of expense a year earlier, while general and administrative expense was USD 2.3 million in both periods.

The same call indicated that cash resources stood at USD 18.4 million as of June 30, 2026, with management expecting funding into the second quarter of 2027. Those figures leave the October reporting date as the next concrete checkpoint for operating spending and clinical progress.

Price stays inside yearly range

The Nasdaq price of USD 1.57 on October 16, 2026 was inside the 52-week range of USD 1.09 to USD 2.60. It stood 39.62 percent below the yearly high. Trading volume was 196,169 shares against an average of 342,990 shares, giving the session a lower-volume profile.

Valuation and upcoming date

INMB had a market capitalization of USD 43.6 million and a negative P/E ratio of 2.28 as of October 16, 2026. The next scheduled reporting date is October 29, 2026, after the market close, with the conference call listed for 4:30 p.m. ET by MarketBeat.

Comparison with peers

INMB (Nasdaq, USD): minus 4.85 percent, P/E minus 2.28, market capitalization USD 43.6 million
Amgen (Nasdaq, USD): minus 0.35 percent, P/E 26.88, market capitalization USD 233.8 billion
Cassava Sciences (Nasdaq, USD): plus 2.33 percent, P/E minus 1.52, market capitalization USD 63.8 million

Nasdaq price sets the frame

The last Nasdaq price stood at USD 1.57 on October 16, 2026 at 4:00 p.m. ET, while the next dated company checkpoint is the estimated October 29, 2026 earnings release. The company is listed as INMB on Nasdaq, according to MarketWatch.